Quarterly report pursuant to Section 13 or 15(d)

INTANGIBLE ASSETS

v3.21.2
INTANGIBLE ASSETS
 9 Months Ended
Sep. 30, 2021
Goodwill and Intangible Assets Disclosure [Abstract]  
INTANGIBLE ASSETS

NOTE 5 – INTANGIBLE ASSETS

 

Intangible assets consisted of the following as of:

 

    Estimated life   September 30, 2021     December 31, 2020  
Trademarks   3 years   $ 22,061     $ 22,061  
Website   3 years     10,799       10,799  
Accumulated amortization         (26,260 )     (10,955 )
        $ 6,600     $ 21,905  

 

As of September 30, 2021, estimated future amortization expenses related to intangible assets were as follows: 

 

    Intangible Assets  
2021 (remaining 3 months)   $ 900  
2022     3,600  
2023     2,100  
Total   $ 6,600  

 

 

The Company had amortization expense of $900 and $15,305 and $360 and $600 for the three and nine months ended September 30, 2021 and 2020, respectively.

 

On January 8, 2020, James Joyce, the Company’s CEO and Craig Roberts, the Company’s CTO, assigned to the Company the rights to patent 62/881,740 pertaining to the devices, systems and methods for the broad-spectrum reduction of pro-inflammatory cytokines in blood in exchange for founder’s shares.